Novo Nordisk CEO Mike Doustdar revealed the company is actively considering mergers and acquisitions to strengthen its position in the competitive weight-loss drug market. He emphasized the company's interest in acquiring or partnering with firms that have developed or are about to launch superior drugs. This strategy aims to fill gaps in Novo Nordisk's portfolio and maintain its market leadership. The move highlights the intensifying competition in the pharmaceutical sector focused on obesity treatments.
Novo Nordisk holds a market cap of $190.93 billion and offers a dividend yield of 4.15%, reflecting its strong position in the health sector. On Pluang, as of Sep 22, 2026 16:11 WIB, the stock trades at USD 39.69 with a slight 1-day decline of 0.33%. Investor interest remains high with 87% of order activity on Pluang being buys, indicating confidence in the company despite the minor dip.
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
Novo Resources Corp. has released an updated corporate presentation outlining its strategic priorities, exploration results, and project advancements. The presentation highlights significant progress in Novo's gold exploration portfolio, including pr...
Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, s...
